137 related articles for article (PubMed ID: 24986871)
1. Extending the reach of nilotinib in chronic myeloid leukemia.
Mauro MJ
Haematologica; 2014 Jul; 99(7):1123-4. PubMed ID: 24986871
[No Abstract] [Full Text] [Related]
2. Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.
Hughes TP; Hochhaus A; Kantarjian HM; Cervantes F; Guilhot F; Niederwieser D; le Coutre PD; Rosti G; Ossenkoppele G; Lobo C; Shibayama H; Fan X; Menssen HD; Kemp C; Larson RA; Saglio G
Haematologica; 2014 Jul; 99(7):1204-11. PubMed ID: 24532039
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up.
Gallipoli P; Stobo J; Heaney N; Nicolini FE; Clark R; Wilson G; Tighe J; McLintock L; Hughes T; Michor F; Paul J; Drummond M; Holyoake TL
Br J Haematol; 2013 Dec; 163(5):674-6. PubMed ID: 24032404
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia.
Hoyle M; Rogers G; Moxham T; Liu Z; Stein K
Value Health; 2011 Dec; 14(8):1057-67. PubMed ID: 22152175
[TBL] [Abstract][Full Text] [Related]
5. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study.
Baccarani M; Druker BJ; Branford S; Kim DW; Pane F; Mongay L; Mone M; Ortmann CE; Kantarjian HM; Radich JP; Hughes TP; Cortes JE; Guilhot F
Int J Hematol; 2014; 99(5):616-24. PubMed ID: 24658916
[TBL] [Abstract][Full Text] [Related]
6. High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trial.
Petzer AL; Fong D; Lion T; Dyagil I; Masliak Z; Bogdanovic A; Griskevicius L; Lejniece S; Goranov S; Gercheva L; Stojanovic A; Peytchev D; Tzvetkov N; Griniute R; Stanchev A; Grubinger T; Kwakkelstein M; Schuld P; Gastl G; Wolf D
Haematologica; 2012 Oct; 97(10):1562-9. PubMed ID: 22511495
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of nilotinib in imatinib-resistant/intolerant chronic myeloid leukemia patients on hemodialysis for chronic renal failure.
Onaka T; Takahashi N; Miura M; Yonezawa A; Imada K; Sawada K
Am J Hematol; 2012 Apr; 87(4):451. PubMed ID: 22407703
[No Abstract] [Full Text] [Related]
8. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Saglio G; Kim DW; Issaragrisil S; le Coutre P; Etienne G; Lobo C; Pasquini R; Clark RE; Hochhaus A; Hughes TP; Gallagher N; Hoenekopp A; Dong M; Haque A; Larson RA; Kantarjian HM;
N Engl J Med; 2010 Jun; 362(24):2251-9. PubMed ID: 20525993
[TBL] [Abstract][Full Text] [Related]
9. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.
Cortes JE; Baccarani M; Guilhot F; Druker BJ; Branford S; Kim DW; Pane F; Pasquini R; Goldberg SL; Kalaycio M; Moiraghi B; Rowe JM; Tothova E; De Souza C; Rudoltz M; Yu R; Krahnke T; Kantarjian HM; Radich JP; Hughes TP
J Clin Oncol; 2010 Jan; 28(3):424-30. PubMed ID: 20008622
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
Eskazan AE; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Leuk Lymphoma; 2014 Dec; 55(12):2935-7. PubMed ID: 24650055
[No Abstract] [Full Text] [Related]
11. Deleterious effects of non-branded versions of imatinib used for the treatment of patients with chronic myeloid leukemia in chronic phase: a case series on an escalating issue impacting patient safety.
Saavedra D; Vizcarra F
Leuk Lymphoma; 2014 Dec; 55(12):2813-6. PubMed ID: 24724785
[TBL] [Abstract][Full Text] [Related]
12. Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study.
Latagliata R; Ferrero D; Iurlo A; Cavazzini F; Castagnetti F; Abruzzese E; Fava C; Breccia M; Annunziata M; Stagno F; Tiribelli M; Binotto G; Mansueto G; Gozzini A; Russo S; Cavalli L; Montefusco E; Gugliotta G; Cedrone M; Russo Rossi A; Avanzini P; Pregno P; Mauro E; Spadea A; Celesti F; Giglio G; Isidori A; Crugnola M; Calistri E; Sorà F; Storti S; D'Addosio A; Rege-Cambrin G; Luciano L; Alimena G
Drugs Aging; 2013 Aug; 30(8):629-37. PubMed ID: 23681399
[TBL] [Abstract][Full Text] [Related]
13. Late response to low-dose imatinib in patients with chronic phase chronic myeloid leukemia.
Takami A; Ohtake S; Morishita E; Terasaki Y; Fukushima T; Kurokawa T; Sugimori N; Matano S; Ohata K; Saito C; Yamaguchi M; Hosokawa K; Yamazaki H; Kondo Y; Nakao S
Int J Hematol; 2012 Sep; 96(3):357-63. PubMed ID: 22893108
[TBL] [Abstract][Full Text] [Related]
14. Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd.
Nakamae H; Shibayama H; Kurokawa M; Fukuda T; Nakaseko C; Kanda Y; Nagai T; Ohnishi K; Maeda Y; Matsuda A; Amagasaki T; Yanada M
Int J Hematol; 2011 May; 93(5):624-632. PubMed ID: 21523338
[TBL] [Abstract][Full Text] [Related]
15. Imatinib therapy for chronic myeloid leukemia: where do we go now?
Cortes JE
J Clin Oncol; 2008 Jul; 26(20):3308-9. PubMed ID: 18519950
[No Abstract] [Full Text] [Related]
16. Chronic myeloid leukemia: where do we go now?
Cortés JE
Clin Lymphoma Myeloma; 2009; 9 Suppl 4():S374-5. PubMed ID: 20007105
[No Abstract] [Full Text] [Related]
17. First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate.
Eskazan AE; Ayer M; Kantarcioglu B; Arica D; Demirel N; Aydin D; Yalniz FF; Elverdi T; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Br J Haematol; 2014 Oct; 167(1):139-41. PubMed ID: 24815307
[No Abstract] [Full Text] [Related]
18. Imatinib mesylate in chronic myeloid leukemia.
Carella AM; Lerma E
Curr Stem Cell Res Ther; 2007 Sep; 2(3):249-51. PubMed ID: 18220908
[TBL] [Abstract][Full Text] [Related]
19. Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Jabbour EJ; Kantarjian H; Eliasson L; Cornelison AM; Marin D
Am J Hematol; 2012 Jul; 87(7):687-91. PubMed ID: 22473898
[TBL] [Abstract][Full Text] [Related]
20. High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients--systematic review and meta-analysis.
Gafter-Gvili A; Leader A; Gurion R; Vidal L; Ram R; Shacham-Abulafia A; Ben-Bassat I; Lishner M; Shpilberg O; Raanani P
Am J Hematol; 2011 Aug; 86(8):657-62. PubMed ID: 21761431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
